ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid

HCID 5538
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
78996-15-3
標準SMILES
CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
InChIKey
SHGAZHPCJJPHSC-UHFFFAOYSA-N
分子式
C20H28O2
平均分子量
300.4 g/mol
単同位体質量
300.20893013

概要

Retinoic acid is a retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified). It has a role as a human metabolite. It is a retinoid and an alpha,beta-unsaturated monocarboxylic acid. It is a conjugate acid of a retinoate.

名称と識別子

優先名称
3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
IUPAC
3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
英語名
SHGAZHPCJJPHSC-GOWYKSNKSA-N
分子式
C20H28O2
分子量
300.44

名称と別名

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acidRefChem:106615311-cis Retinoic Acid3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acidTretinoina (INN-Spanish)Tretinoina [INN-Spanish]Isotretinoin EP Impurity CAvita (0.025% gel)retinylpalmitats1653LGD 100057Spectrum_001676
名称をさらに表示
D5-IsotretinoinRetinoic acid-dRetinoic Acid-d5SHGAZHPCJJPHSC-GOWYKSNKSA-NRetinoic-4,4,18,18,18-d5 acidIsotretinoin D5Q: What is Isotretinoin D5 Q: What is the CAS Number of Isotretinoin D5 Q: What is the storage condition of Isotretinoin D5 Q: What are the applications of Isotretinoin D5
SpecPlus_000696Prestwick0_000256Prestwick0_000257Prestwick1_000256Prestwick1_000257Spectrum2_001983Spectrum3_001793Spectrum4_000901

物性

構造計算による物性補完中

XLogP
6.3
極性表面積
37.3 Ų
水素結合供与体数
1
水素結合受容体数
2
回転可能結合数
5
重原子数
22
形式電荷
0
複雑度
567

実験および物理化学的性質

LogP6.3

物理化学的性質

貯蔵温度
-80 °C · Store at -80°C
溶解性
Methanol: Soluble
外見
A solid
色
White to off-white

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

毒性情報

Exposure Routes1-31% (topical)
Toxicity Summary · 1 件

Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

化学と産業

薬理情報

Metabolism/MetabolitesHepatic Half Life: 0.5-2 hours

用途と製造

Uses · 1 件

For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.

応用分野 · 2 件

説明13-cis Retinoic acid-d5 is intended for use as an internal standard for the quantification of 13-cis retinoic acid by GC- or LC-MS. 13-cis Retinoic acid is a naturally occurring retinoid that inhibits retinol oxidation and dehydrogenation of 17β-hydroxy steroids.

使用An endogenous retinoic acid isomer, which is capable of binding to both retinoic acid receptors (RAR) and retinoid X receptors (RXR). A biologically active ligand for members of the RAR and RXR subfamilies, implying that it may play a critical role in regulating retinoid-responsive pathways.

関連反応

8 件
反応記録を作成
HRID 140142 の反応式
HRID 140142生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
HRID 171983 の反応式
HRID 171983反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
HRID 179424 の反応式
HRID 179424反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 184668 の反応式
HRID 184668生成物として反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 1142109 の反応式
HRID 1142109生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1149157 の反応式
HRID 1149157生成物としてTraining data from https://doi.org/10.1039/C8SC04228D (7/10)
HRID 1228653 の反応式
HRID 1228653反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (5/10)
HRID 1238402 の反応式
HRID 1238402生成物として反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (5/10)

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
78996-15-3
PubChem CID
5538
ChEMBL
CHEMBL1235644
ChEBI
CHEBI:26536